Prabhat Singhal

Prabhat Singhal is currently a Principal Scientist at Morphic Therapeutics, focusing on translational sciences and clinical biomarkers in the context of inflammatory bowel disease and fibrosis. They also serve as a Senior Advisor at Eli Lilly and Company, specializing in clinical biomarkers. Previously, Prabhat led research teams at Massachusetts General Hospital and held various positions in leading biopharmaceutical companies, including Sanofi and Mustang Bio, where they advanced research in fibrosis and cancer therapeutics. Prabhat earned a postdoctoral fellowship at Harvard Medical School under the guidance of Prof. Brian Seed and has extensive experience in managing clinical sample analysis and biomarker development.